FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

PD Joint Holdings, LLC Series 2016-A		 2. Date of Event Requiring Statement (MM/DD/YYYY)
10/22/2022 

 3. Issuer Name and Ticker or Trading Symbol

Pasithea Therapeutics Corp. [KTTA]
(Last)        (First)        (Middle)

C/O TIGER LILY CAPITAL, LLC, 200 GARRETT STREET, SUITE O		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

CHARLOTTESVILLE, VA 22902      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 2608696 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrant (right to buy) 12/21/2022 6/21/2027 Common Stock 800000 $1.88 D  
Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
PD Joint Holdings, LLC Series 2016-A
C/O TIGER LILY CAPITAL, LLC
200 GARRETT STREET, SUITE O
CHARLOTTESVILLE, VA 22902
X

Manning Paul B
200 GARRETT STREET, SUITE S
CHARLOTTESVILLE, VA 22902
X

Manning Bradford
C/O TIGER LILY CAPITAL, LLC
200 GARRETT STREET, SUITE O
CHARLOTTESVILLE, VA 22902
X

Tiger Lily Capital, LLC
200 GARRETT STREET, SUITE O
CHARLOTTESVILLE, VA 22902
X
Signatures
PD Joint Holdings, LLC, Series 2016-A, By: Tiger Lily Capital, LLC, By: /s/ Paul B. Manning and /s/ Bradford Manning, its Managers2/14/2023
**Signature of Reporting PersonDate

/s/ Paul B. Manning2/14/2023
**Signature of Reporting PersonDate

/s/ Bradford Manning2/14/2023
**Signature of Reporting PersonDate

Tiger Lily Capital, LLC, By: /s/ Paul B. Manning and /s/ Bradford Manning, its Managers2/14/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Pasithea Therapeutics (NASDAQ:KTTA)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Pasithea Therapeutics
Pasithea Therapeutics (NASDAQ:KTTA)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Pasithea Therapeutics